Greater Southern California Node of the Clinical Trials Network

临床试验网络大南加州节点

基本信息

批准号：
10581587
负责人：
YIH-ING HSER
金额：
$ 66.25万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-06-01 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10581587
关键词：
Address Area Behavior Therapy California Cellular Phone Clinical Research Clinical Treatment Clinical Trials Network Collaborations Concept Review Data Science Development Drug abuse Faculty Generations Goals Health Health Services Accessibility Health care facility Healthcare Helping to End Addiction Long-term Improve Access Individual Interdisciplinary Study Intervention Intervention Studies Journals Lead Leadership Mission Modeling Morbidity - disease rate Multi-Institutional Clinical Trial National Institute of Drug Abuse New York Pharmaceutical Preparations Pharmacotherapy Population Population Heterogeneity Principal Investigator Protocols documentation Public Health Research Research Infrastructure Research Personnel Research Priority Research Support Seminal Services Substance Use Disorder Talents Technology Telemedicine Testing Training Treatment Effectiveness Treatment outcome United States United States National Institutes of Health Vulnerable Populations Work clinical practice clinical trial implementation comorbidity design electronic health record system health care service organization health care settings implementation science implementation strategy improved improved outcome innovation innovative technologies mHealth meetings mortality opioid epidemic opioid use disorder overdose death pharmacologic protocol development response rural area rural setting student training substance use treatment uptake

项目摘要

Project Summary/Abstract The overarching goal of the Greater Southern California Node (GSCN) of the National Drug Abuse Treatment Clinical Trials Network (CTN) is to expand access to and improve outcomes of treatments for substance use disorders (SUDs)—with a special emphasis on opioid use disorder (OUD) —by collaboratively developing and testing effective and sustainable interventions for OUD that can be delivered in diverse healthcare settings. To achieve this goal, we have assembled (1) local, regional, and state-wide healthcare networks that serve millions of individuals, (2) investigators who have conducted seminal work on development and testing of pharmacological and behavioral interventions for SUDs, and (3) researchers with expertise in implementation strategies, data science, and innovative technologies to support treatment delivery and related research. Building upon investigators' past and current efforts, the specific aims of GSCN are: Aim 1. Lead and contribute to the development of new research protocols designed to increase access to treatments for OUD and to improve treatment outcomes; Aim 2. Support and participate in multi-site CTN projects and other CTN activities; and Aim 3. Disseminate research findings and provide innovative training to impact clinical practice. The GSCN research agenda will initially focus on four priority areas: (1) developing and testing effective medication and behavioral interventions for OUD and related comorbidities, (2) applying implementation science to deliver and expand OUD treatment in multiple healthcare settings, (3) leveraging eHealth (e.g., electronic health record systems) and data science for discovery and generation of innovative hypotheses and approaches to improve treatment for OUD, and (4) building on mHealth (e.g., smartphone- assisted interventions) and other technologies (e.g., telemedicine) to expand OUD treatment access and utilization. The GSCN research agenda reflects its capacity to collaboratively expand CTN efforts to develop and implement innovative approaches to improve treatment for OUD and other SUDs.

项目摘要/摘要国家药物滥用的大南加州节点（GSCN）的总体目标治疗临床试验网络（CTN）将扩大对治疗的访问并改善治疗结果物质使用障碍（SUDS） - 特别强调阿片类药物使用障碍（OUD） - 通过协作开发和测试可以在潜水员中提供的有效和可持续干预措施医疗保健设置。为了实现这一目标，我们组装了（1）本地，地区和全州的医疗保健服务数百万个人的网络，（2）已经进行了半劳动的调查员以及对SUD的药物和行为干预措施的测试，以及（3）具有专业知识的研究人员实施策略，数据科学和创新技术，以支持治疗交付及相关研究。在调查人员的过去和当前努力的基础上，GSCN的具体目标是：AIM 1。并为开发新的研究方案的制定做出贡献，旨在增加治疗的机会 oud并改善治疗结果；目标2。支持和参与多站点的CTN项目和其他 CTN活动；目标3。传播研究结果并提供创新的培训以影响临床实践。 GSCN研究议程最初将集中于四个优先领域：（1）开发和测试对OUD和相关合并症的有效药物和行为干预措施，（2）应用实施科学以在多种医疗机构中提供和扩展Oud治疗，（3）利用 EHealth（例如电子健康记录系统）和用于发现和生成创新的数据科学改善OUD治疗的假设和方法，以及（4）建立MHealth（例如智能手机）辅助干预措施）和其他技术（例如远程医疗），以扩大OUD治疗访问和利用率。 GSCN研究议程反映了其协作扩大CTN努力发展的能力并实施创新的方法来改善OUD和其他SUD的治疗方法。

项目成果

期刊论文数量（8）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives.

DOI：
10.1016/j.jsat.2021.108544
发表时间：
2022-03
期刊：
Journal of substance abuse treatment
影响因子：
3.9
作者：
Lin C;Clingan SE;Cousins SJ;Valdez J;Mooney LJ;Hser YI
通讯作者：
Hser YI

Identifying patients with opioid use disorder using International Classification of Diseases (ICD) codes: Challenges and opportunities.

使用国际疾病分类 (ICD) 代码识别阿片类药物使用障碍患者：挑战和机遇。

DOI：
10.1111/add.16338
发表时间：
2024
期刊：
Addiction (Abingdon, England)
影响因子：
0
作者：
Osterhage,KatieP;Hser,Yih-Ing;Mooney,LarissaJ;Sherman,Seth;Saxon,AndrewJ;Ledgerwood,Maja;Holtzer,CalebC;Gehring,MargaretA;Clingan,SarahE;Curtis,MeganE;Baldwin,Laura-Mae
通讯作者：
Baldwin,Laura-Mae

Social Determinants of Health and Continuity of Medications for Opioid Use Disorder Among Patients Receiving Treatment in Rural Primary Care Settings.

在农村初级保健机构接受治疗的患者中阿片类药物使用障碍的健康和持续用药的社会决定因素。

DOI：
10.1097/adm.0000000000001274
发表时间：
2024
期刊：
Journal of addiction medicine
影响因子：
5.5
作者：
Pham,Huyen;Ober,Allison;Baldwin,Laura-Mae;Mooney,LarissaJ;Zhu,Yuhui;Fei,Zhe;Hser,Yih-Ing
通讯作者：
Hser,Yih-Ing

Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder.